Abstract: The invention relates to a product for use in the therapeutic or prophylactic treatment of infections, said treatment comprising oral administration of the product, wherein the product is selected from a nutritional formulation, a food product, a dietary supplement, a beverage and a pharmaceutical product, said product containing carrot RG-I polysaccharides having the following combination features: a molecular weight in the range 10-300 kDa; a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues; the following monosaccharide composition: 20-60 mol. % galacturonic acid residues, wherein the individual galacturonic acids can be methylated and/or acetyl-esterified; 8-50 mol. % rhamnose residues; 0-40 mol. % arabinose residues; 0-40 mol.
Abstract: The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).
Abstract: An antioxidant composition and a container containing such a composition, which may confer a health benefit or an aesthetic benefit to a human. The composition includes a substantially aqueous solvent, the solvent having dissolved therein carbon dioxide gas and hydrogen gas. The composition may take the form of a medicament, a beverage, an infusion, or a topical.
Abstract: The present invention relates to a composition for use in a method for the preventive or curative treatment of an iron deficiency and pathologies and disorders connected thereto in a subject, wherein said use comprises the administration of the composition to said subject.
Abstract: The present invention relates to compositions for mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided. In particular, the invention relates to a method of mineralizing a dental surface or subsurface comprising contacting the dental surface or subsurface with a compound that is capable of increasing or maintaining the pH of a solution and a mineralizing agent.
Abstract: The present invention relates to a production method of a composition that can prevent, ameliorate, or treat autoimmune diseases including allergic diseases, and the composition produced by the method. In the method, the plasmacytoid dendritic cells with tolerogenic capacity may be induced from the immature dendritic cells at a high yield using a simple and easy process. The plasmacytoid dendritic cells can effectively prevent, ameliorate or treat the autoimmune diseases.
Type:
Application
Filed:
January 30, 2018
Publication date:
August 6, 2020
Inventors:
Sung Jae Shin, Wahn Soo Choi, Woo Sik Kim, Hyuk Soon Kim, Hong Min Kim
Abstract: The invention provides a chimeric antigen receptor (CAR) which can specifically bind to a BCMA protein comprising a BCMA binding structural domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain. The invention also provides uses of the CAR in treating diseases or conditions linked to the expression of BCMA.
Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
Type:
Application
Filed:
December 11, 2019
Publication date:
August 6, 2020
Inventors:
Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk
Abstract: This disclosure describes a compound that binds to fibroblast activation protein alpha (FAP), compositions including the compound, and methods of using the compound, and compositions. In some embodiments, the compound is a monoclonal antibody that binds FAP. The compound may be used, for example, as a research tool, in clinical imaging, as a diagnostic agent, or as a therapeutic agent.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Application
Filed:
April 14, 2020
Publication date:
August 6, 2020
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: Provided herein are micro-organoids, referred to herein as Functional Physiological Units (FPUs), that are capable of replacing or augmenting one or more physiological functions in an individual, which are useful in the treatment of individuals lacking, or suffering a deficit in, said physiological function.
Type:
Application
Filed:
April 21, 2020
Publication date:
August 6, 2020
Applicant:
Celularity Inc.
Inventors:
Robert J. HARIRI, Mohit BHATIA, Jia-Lun WANG, Wolfgang HOFGARTNER, Qian YE
Abstract: Disclosed herein are methods and compositions for cell induction and treating neurological disorders, utilizing adherent stromal cells, which may, for example, be derived from placental tissue, bone marrow, or adipose tissue. Also provided are pharmaceutical compositions comprising the described cells, optionally in combination with pharmaceutically acceptable excipients.
Abstract: A method for enhancing an expression of insulin like growth factor 1 receptor in a mesenchymal stem cell is provided. The method includes culturing the mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the mesenchymal stem cell.
Abstract: The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.
Type:
Application
Filed:
September 21, 2018
Publication date:
August 6, 2020
Inventors:
Joshua M. Hare, Konstantinos Chatzistergos
Abstract: Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.
Abstract: Provided is a composition including mesenchymal stem cells as an effective ingredient for prevention, alleviation, or treatment of thyroid-associated ophthalmopathy. A pharmaceutical composition including mesenchymal stem cells as an effective ingredient for treatment of thyroid-associated ophthalmopathy allows patients with thyroid-associated ophthalmopathy to recover from an abnormal increase in hyaluronic acid production in orbital fibroblasts, increased adipocyte differentiation, and increased lipid accumulation, and thus may be useful for the treatment of thyroid-associated ophthalmopathy.
Abstract: Provided herein are methods of suppressing the growth or proliferation of tumor cells and methods of treating individuals having tumor cells using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer (PINK) cells, combined natural killer (NK) cells, or combinations thereof, in combination with an antibody (e.g., anti-disialoganglioside (anti-GD2) antibody). Also provided herein are compositions comprising placental perfusate, placental perfusate cells, PINK cells, combined NK cells, or combinations thereof, in combination with an antibody (e.g., anti-GD2 antibody).
Type:
Application
Filed:
September 27, 2018
Publication date:
August 6, 2020
Applicant:
CELULARITY, INC.
Inventors:
Xiaokui ZHANG, Lin KANG, Robert J. HARIRI
Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Type:
Application
Filed:
February 12, 2020
Publication date:
August 6, 2020
Inventors:
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
Type:
Application
Filed:
March 26, 2020
Publication date:
August 6, 2020
Inventors:
Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
Abstract: In certain aspects, described herein are methods, bacteria, and compositions for the reduction of the amount, activity and/or proliferation of colonic group 3 innate lymphoid cells (ILC3s) and for the treatment and/or prevention of diseases associated with pathological immune responses, such as inflammatory bowel diseases.
Abstract: Methods and compositions comprising hogocidin peptides (SH-lantibiotics), derivatives and variants are provided. Also provided are methods and compositions comprising probiotic compositions utilizing strains of S. hominis and S. epidermidis that produce hogocidin, hogocidin-like peptides, or other inhibitors of skin pathogens. Methods of treatment for microbial skin infections and atopic dermatitis are also provided.
Type:
Application
Filed:
October 15, 2019
Publication date:
August 6, 2020
Applicant:
The Regents of the University of California
Abstract: Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy. In certain embodiments, the consortia comprise certain members of the taxa Clostridiales and/or Bacteroidetes.
Type:
Application
Filed:
September 12, 2019
Publication date:
August 6, 2020
Applicants:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Talal A. Chatila, Lynn Bry, Georg Gerber, Azza Abdel-Gadir, Rima Rachid
Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
Type:
Application
Filed:
February 3, 2020
Publication date:
August 6, 2020
Applicant:
The University of Tokyo
Inventors:
Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
Abstract: The present invention concerns novel Lactobacillus plantarum strains capable of promoting the growth of a subject, and more particularly the juvenile or prenatal growth of farm animals, and their uses as probiotics.
Type:
Application
Filed:
August 17, 2018
Publication date:
August 6, 2020
Applicants:
Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Universite Claude Bernard Lyon 1
Abstract: The present invention provides a pharmaceutical composition comprising a probiotic and a prebiotic for preventing acquisition of and/or alleviating symptoms associated with an infection caused by an Extended-spectrum beta-lactamases (ESBL) producing organism and other drug resistant pathogens. More particularly, the pharmaceutical composition comprises at least one Lactillobacillus specie(s) as a probiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of preventing acquisition of and/or treating an infection caused by Extended-spectrum beta-lactamases (ESBL) producing bacteria and other drug resistant pathogens, comprising administering an effective amount of a pharmaceutical composition comprising a probiotic and a prebiotic to a subject in need thereof.
Abstract: The present invention provides a pharmaceutical composition including a probiotic and a prebiotic for treatment of stunting in children. More particularly, the pharmaceutical composition includes at least one Lactobacillus specie(s) as a probiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of treatment of stunting including administering an effective amount of a pharmaceutical composition including a probiotic and a prebiotic to children in need thereof.
Abstract: [Problem] To provide an agent suppressing an increase in blood sugar level, said agent being capable of controlling blood sugar level even in a patient having normal blood sugar level or a patient corresponding to pre-diabetes, showing little side effects and being derived from a safe food. Also, the present invention addresses the problem of providing foods and drinks, i.e., foods including health foods, functional foods, health supplements, etc. as well as drinks, each comprising the aforesaid composition. [Solution] An extract of yeast to be used as an active ingredient. As the extract of yeast, it was found that a yeast extract, which can be obtained by a simple procedure comprising treating a yeast with hot water, an acid or an alkali, and/or an enzyme, has an improved effect of suppressing an increase in blood sugar level.
Type:
Application
Filed:
April 23, 2020
Publication date:
August 6, 2020
Applicant:
MITSUBISHI CORPORATION LIFE SCIENCES LIMITED
Abstract: The invention provides for compositions comprising one or more or at least two active ingredient(s), e.g., a cannabinoid, cannabinoid extract, terpene, or terpene extract. The invention includes cannabinoid formulations, including self-emulsifying formulations and micellar dispersions, as well as methods of making and using the same. Some formulations comprise a cannabinoid and surfactant. The formulations have improved dissolution, stability, absorption and/or oral bioavailability. Some of the formulations are rapid dispersing formulations.
Type:
Application
Filed:
February 13, 2020
Publication date:
August 6, 2020
Inventors:
Tuna Yucel, Scott S. Finnance, Stephen E. Zale, Nicholas J. Boylan, William Stephen Faraci
Abstract: The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis. The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis, as well as methods of medical treatment that include administering the pharmaceutical dosage forms.
Abstract: The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis. The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis, as well as methods of medical treatment that include administering the pharmaceutical dosage forms.
Abstract: Disclosed are uses of ginseng saponin, which contains at least 90% of a compound K, Rd, F2, and Rg3 as a main ingredient and has effects in extending the lifespan of the cell, promoting the cell differentiation, increasing the number of red blood cells, and reducing the triglycerides by extracting, heat-treating, and enzyme-converting the ginseng saponin to prepare active saponins Rd, F2, and Rg3 including a compound K.
Type:
Application
Filed:
April 22, 2020
Publication date:
August 6, 2020
Applicant:
KYUNGSUNG UNIVERSITY INDUSTRY COOPERATION FOUNDATION
Inventors:
Jae Seon KANG, Bo Suel KIM, Heyong-Soo KIM, Gyu-Jin RHO, Sin-Ja BAE, Seo Hyun LEE, Jong Jin PARK, Choel-Min KIM
Abstract: A pharmaceutical composition for treating pain including malkangni oil and cypriol oil as active ingredients, and a method of topical administration of a pharmaceutical composition on skin for relieving pain, the method including: locally applying the pharmaceutical composition on an area of skin corresponding to the pain, wherein the pharmaceutical composition including malkangni oil and cypriol oil as active ingredients.
Abstract: The present invention provides a pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis or modifying hair, the pharmaceutical composition comprising a therapeutically effective amount of a saturated fatty acid or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract: Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of the present disclosure may be used as a dietary supplement for the prophylaxis or treatment of amyloid related neurodegenerative diseases so as to ameliorate or alleviate symptoms associated with the amyloid related neurodegenerative diseases.
Abstract: The present synergistic herbal compositions comprising herbal ingredients extracted from at least two herbal species selected from the group consisting of Ocimum basilicum, Agathosma betulina, Cinnamomum cassia, Cinnamomum verum and Apium graveolens helps maintain the electrolyte and fluid balance by exerting its inhibitory secretory activity and by increasing the absorptive capacity of the intestine to prevent dehydration during an episode of infectious and non-infectious diarrhoea and in dehydration associated with various clinical and non-clinical conditions
Abstract: Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent.
Type:
Application
Filed:
October 8, 2019
Publication date:
August 6, 2020
Applicant:
Nature's Sunshine Products, Inc.
Inventors:
Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Wei Gao, Mohan Kaadige, Sheryl Krig, Xiaolan Kou, Zhe Khang, Joseph Ou
Abstract: Disclosed in the present specification is a composition comprising a Prunus mume flower extract as an effective ingredient for treating fine dust-caused skin damage, wherein the expression of IL-36G (NM 019618), which is a gene having an expression level affected by fine dust in skin cells, is regulated to a novel level. By using the composition for treating fine dust-caused skin damage, gene expression changed by fine dust can return to a normal level to treat skin cell damage.
Type:
Application
Filed:
August 13, 2018
Publication date:
August 6, 2020
Applicant:
AMOREPACIFIC CORPORATION
Inventors:
Hyoung-June KIM, Jinsup SHIM, Tae Ryong LEE
Abstract: A method for treatment of constipation and other ailments of the gastrointestinal system includes administering a pharmaceutically effective amount of a composition over a sufficient period of time that results in the production of nitric oxide in gastrointestinal cells and ultimately has beneficial results in treating constipation and other ailments of the gastrointestinal system. The composition comprises ginger or a ginger derivative, muira puama, and paullinia cupana that stimulates nitric oxide in gastrointestinal cells to increase NO and improve bowel functioning thereof.
Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention.
Type:
Application
Filed:
April 3, 2020
Publication date:
August 6, 2020
Inventors:
Richard Eric SCHLUMPF, Robert BARATTA, Shawn A. DELOREY
Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
Type:
Application
Filed:
July 16, 2019
Publication date:
August 6, 2020
Inventors:
ALLEN Radin, NEIL GRAHAM, BOLANLE AKINLADE, GIANLUCA PIROZZI, XING SUN, THOMAS HULTSCH, BRAD S. SHUMEL, ASHISH BANSAL
Abstract: This disclosure provides methods of a method of treating a retinal angiogenic in a subject comprising administering an effective amount of an Angio-3 peptide.
Type:
Application
Filed:
August 31, 2018
Publication date:
August 6, 2020
Inventors:
Michael BELKIN, Veluchamy Amutha BARATHI, Rajamani LAKSHMINARAYANAN, R. Manjunatha KINI, Ge RUOWEN, Tien Yin WONG, Gemmy Chui Ming CHEUNG
Abstract: The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC<4 or >12 cells/4; HR>90 bpm; and any one of HCO3<21 mmol/L or PaCO2<32 mmHg or >20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL.
Type:
Application
Filed:
March 24, 2020
Publication date:
August 6, 2020
Inventors:
Khurram Jamil, Stephen Chris Pappas, Jim Potenziano
Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.
Abstract: The invention features methods and compositions for eliciting an anti-tumor response in a subject comprising administering to the subject a pHLIP® construct comprising an antibody recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound. The construct increases the amount of the antibody recruiting molecule on the surface of a diseased cell.
Type:
Application
Filed:
January 28, 2020
Publication date:
August 6, 2020
Applicants:
Rhode Island Council on Postsecondary Education, Yale University, Yale University
Inventors:
Yana K. Reshetnyak, Oleg A. Andreev, Anna Moshnikova, Donald M. Engelman
Abstract: The present matter relates to compositions comprising a Teneurin C-terminal Associated Peptide-1 (TCAP-1) peptide and methods and uses of same for preventing and/or treating post-traumatic stress disorder (“PTSD”).
Type:
Application
Filed:
October 12, 2018
Publication date:
August 6, 2020
Inventors:
David Lovejoy, Robert Stein, Andrew Slee, Garo Armen
Abstract: Methods for improving quality of life and/or increasing activity in an aging and/or chronically ill mammal via administration of a composition of egg powder protein are provided.
Type:
Application
Filed:
January 29, 2020
Publication date:
August 6, 2020
Inventors:
Joseph MANNELLO, Maghsoud DARIANI, Neerav D. PADLIYA